We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+11.47%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.98B
AUM Growth
+$132M
Cap. Flow
+$20.2M
Cap. Flow %
0.34%
Top 10 Hldgs %
41.51%
Holding
666
New
23
Increased
324
Reduced
223
Closed
42

Top Buys

Rank Stock Value
1
WMT icon
Walmart Inc
WMT
+$142M
2
ASML icon
ASML
ASML
+$117M
3
TSEM icon
Tower Semiconductor
TSEM
+$112M
4
LRCX icon
Lam Research
LRCX
+$88M
5
MU icon
Micron Technology
MU
+$53.9M

Top Sells

Rank Stock Value
1
SNDK
Sandisk
SNDK
+$81.3M
2
LITE icon
Lumentum
LITE
+$72.3M
3
PM icon
Philip Morris
PM
+$40M
4
MSFT icon
Microsoft
MSFT
+$28.5M
5
META icon
Meta Platforms (Facebook)
META
+$27.2M

Sector Composition

Rank Sector Weight
1 Technology 54.47%
2 Communication Services 12.44%
3 Consumer Discretionary 11.77%
4 Consumer Staples 6.03%
5 Healthcare 5.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AQST icon
551
Aquestive Therapeutics
AQST
$494M
$11.3K ﹤0.01%
2,727
+330
+14% +$1.34K
RIGL icon
552
Rigel Pharmaceuticals
RIGL
$734M
$11K ﹤0.01%
407
+51
+14% +$1.71K
UPB
553
Upstream Bio Inc
UPB
$380M
$10.8K ﹤0.01%
1,203
+142
+13% +$2.56K
TRDA icon
554
Entrada Therapeutics
TRDA
$246M
$10.8K ﹤0.01%
852
+101
+13% +$1.16K
KMDA icon
555
Kamada
KMDA
$409M
$10.7K ﹤0.01%
1,288
+155
+14% +$1.3K
ABSI icon
556
Absci
ABSI
$1.38B
$10.1K ﹤0.01%
3,362
+407
+14% +$1.18K
SAFE
557
Safehold
SAFE
$1.17B
$9.67K ﹤0.01%
715
-58
-8% -$859
LKFT
558
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$9.54K ﹤0.01%
318
+36
+13% +$1.19K
AURA icon
559
Aura Biosciences
AURA
$705M
$9.47K ﹤0.01%
1,416
+169
+14% +$970
RGNX icon
560
Regenxbio
RGNX
$557M
$9.45K ﹤0.01%
1,128
+134
+13% +$1.41K
LYEL icon
561
Lyell Immunopharma
LYEL
$317M
$9.43K ﹤0.01%
470
+54
+13% +$1.26K
AVIR icon
562
Atea Pharmaceuticals
AVIR
$383M
$9.38K ﹤0.01%
1,743
+209
+14% +$960
LXEO icon
563
Lexeo Therapeutics
LXEO
$357M
$9.35K ﹤0.01%
1,628
+194
+14% +$1.38K
CBL
564
CBL Properties
CBL
$1.72B
$9.26K ﹤0.01%
241
-17
-7% -$630
FULC icon
565
Fulcrum Therapeutics
FULC
$241M
$9.23K ﹤0.01%
1,204
+142
+13% +$1.32K
MRVI icon
566
Maravai LifeSciences
MRVI
$1.03B
$9.17K ﹤0.01%
3,241
+392
+14% +$1.33K
VNDA icon
567
Vanda Pharmaceuticals
VNDA
$320M
$9.17K ﹤0.01%
1,327
+187
+16% +$1.44K
ACRS icon
568
Aclaris Therapeutics
ACRS
$778M
$9.07K ﹤0.01%
2,419
+291
+14% +$982
PACB icon
569
Pacific Biosciences
PACB
$422M
$8.85K ﹤0.01%
6,705
+773
+13% +$1.38K
RCKT icon
570
Rocket Pharmaceuticals
RCKT
$375M
$8.64K ﹤0.01%
2,414
+289
+14% +$1.15K
LRMR icon
571
Larimar Therapeutics
LRMR
$398M
$8.6K ﹤0.01%
1,910
+230
+14% +$919
SIGA icon
572
SIGA Technologies
SIGA
$250M
$8.55K ﹤0.01%
1,598
+192
+14% +$1.2K
NKE icon
573
Nike
NKE
$64.5B
$8.45K ﹤0.01%
160
– –
KYTX icon
574
Kyverna Therapeutics
KYTX
$440M
$8.43K ﹤0.01%
977
+117
+14% +$975
AIV
575
Aimco
AIV
$384M
$8.43K ﹤0.01%
2,071
-175
-8% -$916
21 22
23
24 25

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return

GF Fund Management's Q1 2026 Portfolio in Review

As of Q1 2026, GF Fund Management held 666 positions worth $5.98B, up 2.3% from $5.85B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

GF Fund Management's Q1 2026 filing shows 23 new, 324 increased, 223 reduced and 42 closed positions. Its largest new stake was Coherent: 98,000 shares worth $23.3M. The largest sale was Sandisk, an estimated $81.3M.

By sector, the portfolio is most concentrated in Technology at 54% of assets, up from 51% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q1 2026 buy was Coherent: 98,000 shares worth $23.3M.
  • GF Fund Management added most to Walmart Inc in Q1 2026, an estimated $142M increase.
  • GF Fund Management's biggest Q1 2026 reduction was Sandisk, cutting an estimated $81.3M.
  • GF Fund Management fully exited AstraZeneca in Q1 2026, selling an estimated $12.4M.
  • GF Fund Management's ten largest holdings make up 42% of its $5.98B portfolio in Q1 2026.
  • GF Fund Management opened 23 new positions and closed 42 in Q1 2026.
  • GF Fund Management's portfolio value rose 2.3% quarter-over-quarter to $5.98B.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.